Parkinson'
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who fall into any of the following categories shall be included. (1) Patients who received * less than or equal to 300 mg/day of levodopa for more than a certain period of time during the follow-up period and subsequently received additional rasagiline. (2) Patients who received * less than or equal to 300 mg/day of levodopa for more than a certain period of time during the follow-up period and subsequently received an increase in the dose of levodopa. *The number of days to ensure the necessary number of patients should be considered after conducting a feasibility study. The index date will be the date of the first dose of lasagiline in (1) and the date of dose escalation from the maximum dose of levodopa of 300 mg/day or less in (2). The patients in (1) will be designated as subgroup 1, and those in (2) as subgroup 2.
Exclusion criteria
Exclusion criteria: Exclude patients who meet the following criteria Patients with a history of DBS prior to the Index date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of change in MDS-UPDRS PART3 score between baseline and follow-up periods | — |
Countries
Japan
Contacts
Public ContactKiyoto Naito
Takeda Pharmaceutical Company Limited. Japan Medical Office
Outcome results
None listed